News
Kamada IV augmentation therapy is named "Glassia"
Globes
Israeli biotechnology drug developer Kamada Ltd. today announced that the US Food and Drug Administration (FDA) has approved the commercial name “Glassia” for the company’s intravenous therapy for emphysema caused by Alpha-1 Antitrypsin Deficiency.
Kamada also set up a wholly-owned subsidiary in the US, Kamada Inc., in preparation for its marketing efforts there. The offices will be based in Maryland, near the offices of the FDA and National Institutes of Health (NIH).
The FDA is expected to rule on Kamada’s marketing license application in July.
Kamada has a distribution agreement for intravenous alpha-1 with an undisclosed US distributor. The distributor has undertaken a minimum of $15 million in sales of the drug within 18 months of the FDA approval.
